Genomic Vision SA
PAR:GV
Balance Sheet
Balance Sheet Decomposition
Genomic Vision SA
Genomic Vision SA
Balance Sheet
Genomic Vision SA
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
1
|
23
|
16
|
7
|
2
|
3
|
1
|
2
|
2
|
1
|
|
| Cash |
1
|
0
|
0
|
0
|
0
|
3
|
1
|
2
|
2
|
1
|
|
| Cash Equivalents |
0
|
23
|
16
|
7
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
2
|
3
|
3
|
3
|
2
|
2
|
2
|
2
|
1
|
|
| Accounts Receivables |
0
|
2
|
3
|
3
|
3
|
1
|
1
|
1
|
0
|
0
|
|
| Other Receivables |
1
|
0
|
0
|
0
|
0
|
2
|
1
|
1
|
1
|
1
|
|
| Inventory |
0
|
0
|
0
|
1
|
1
|
2
|
1
|
1
|
1
|
1
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
5
|
25
|
19
|
11
|
6
|
7
|
5
|
5
|
5
|
4
|
|
| PP&E Net |
1
|
1
|
3
|
2
|
1
|
1
|
1
|
2
|
1
|
1
|
|
| PP&E Gross |
1
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
1
|
1
|
|
| Accumulated Depreciation |
1
|
0
|
0
|
0
|
0
|
3
|
4
|
3
|
3
|
4
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
6
N/A
|
26
+356%
|
22
-17%
|
13
-40%
|
8
-37%
|
9
+5%
|
6
-36%
|
7
+30%
|
7
-7%
|
5
-26%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
1
|
1
|
1
|
2
|
2
|
1
|
1
|
1
|
2
|
|
| Accrued Liabilities |
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
1
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
2
|
1
|
1
|
0
|
1
|
1
|
1
|
0
|
0
|
1
|
|
| Total Current Liabilities |
4
|
3
|
3
|
3
|
4
|
4
|
2
|
3
|
3
|
4
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
|
| Other Liabilities |
1
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
5
N/A
|
4
-22%
|
4
-5%
|
3
-10%
|
5
+42%
|
5
+0%
|
2
-48%
|
4
+76%
|
4
-11%
|
6
+70%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
1
|
2
|
4
|
5
|
6
|
1
|
|
| Retained Earnings |
10
|
12
|
17
|
25
|
9
|
15
|
20
|
25
|
28
|
30
|
|
| Additional Paid In Capital |
11
|
35
|
35
|
35
|
12
|
18
|
19
|
23
|
25
|
27
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
1
N/A
|
23
+2 216%
|
18
-19%
|
10
-45%
|
4
-63%
|
4
+11%
|
3
-23%
|
3
-3%
|
3
-2%
|
1
N/A
|
|
| Total Liabilities & Equity |
6
N/A
|
26
+356%
|
22
-17%
|
13
-40%
|
8
-37%
|
9
+5%
|
6
-36%
|
7
+30%
|
7
-7%
|
5
-26%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
3
|
4
|
4
|
4
|
6
|
16
|
38
|
51
|
61
|
114
|
|